Home › Melanoma › Wisconsin › La Crosse
Melanoma clinical trials in La Crosse, WI
3 studies for Melanoma are looking for participants at sites in and around La Crosse (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Gundersen Lutheran Medical Center, La Crosse
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RecruitingPhase 2
- Gundersen Lutheran Medical Center, La Crosse
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- Gundersen Lutheran Medical Center, La Crosse
- Mayo Clinic Health System-Franciscan Healthcare, La Crosse
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX59 studies
- New York City, NY38 studies
- Los Angeles, CA34 studies
- Nashville, TN33 studies
- Pittsburgh, PA31 studies
- Boston, MA26 studies
- Philadelphia, PA23 studies
- San Francisco, CA22 studies
- Atlanta, GA21 studies
- Durham, NC21 studies
- St. Louis, MO21 studies
- Columbus, OH21 studies
Other studies in La Crosse
- Non-Small Cell Lung Cancer10 studies
- Lung Cancer9 studies
- Acute Myeloid Leukemia6 studies
- Breast Cancer6 studies
- Multiple Myeloma4 studies
- Head and Neck Squamous Cell Carcinoma3 studies
- Laryngeal Cancer3 studies
- Oral Cancer3 studies
- Endometrial Cancer3 studies
- Ovarian Cancer3 studies
- Diffuse Large B-Cell Lymphoma3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.